TAVR

Transcatheter aortic valve replacement (TAVR) is a key structural heart procedure that has rapidly expanded in the decade since it was first FDA cleared. TAVR has come a paradigm shift in how many aortic stenosis patients are treated, now making up more than 50% of U.S. aortic valve replacements. It is less invasive than open heart surgery and recovery times are greatly reduced. TAVR can also be used in patients who otherwise are too high risk to undergo surgery. TAVR is referred to as transcatheter aortic valve implantation (TAVI) in many placed outside of the U.S. TAVR inspired the growing areas of transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

A renal failure patient receives dialysis. A new study shows a drop in death in kidney failure patients from heart attack, PE and stroke.

New risk score helps cardiologists predict when TAVR patients may require dialysis

Patients who need renal replacement therapy after TAVR are much less likely to survive. Researchers hope their new risk score can help care teams prepare ahead of time for this rare, but potentially fatal complication. 

April 1, 2024
Medtronic has received U.S. Food and Drug Administration (FDA) approval for its Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis.

FDA approves Medtronic’s next-generation TAVR system with new frame design

The Evolut FX+ TAVR system includes an updated diamond-shaped frame, which was made four times larger than previous models to offer improved coronary access. It was also designed to provide more space for operators to guide and maneuver the catheter during procedures.

March 28, 2024
American Heart Association and Joint Commission launch new Comprehensive Heart Attack Center certification.

Heart attacks after TAVR: New AMI data ‘reassuring’ at first glance, but questions remain

Hoping to gain a better understanding of how TAVR may impact a patient’s long-term cardiovascular health, researchers explored data from more than 200,000 patients and shared their findings in JACC: Cardiovascular Interventions.

March 28, 2024
doctor comparing the costs of different medical treatments

TAVR is often more cost-effective than SAVR—but not always

Average lengths of stay and common complications are just some of the factors care teams should consider when evaluating the costs of aortic valve replacement. 

March 26, 2024
Virtual reality (VR) can help cardiologists plan for transcatheter aortic valve replacement (TAVR) procedures and predict the presence and severity of post-TAVR paravalvular leak (PVL), according to new research published in the Journal of Invasive Cardiology.[1]

VR before TAVR predicts paravalvular leak in high-risk patients

Performing virtual reality simulations before TAVR may help cardiologists anticipate when PVL could be an issue in patients with severe BAV AS.

March 25, 2024
Sapien 3 Ultra Resilia TAVR valves

Edwards, Abbott share updated TAVR data at CRT 2024

Some of the world’s biggest names in interventional cardiology and structural heart disease gathered in Washington, D.C., for the four-day event. 

March 15, 2024
Medtronic's Evolut Pro TAVR valve is designed to treat aortic stenosis.

TAVR vs. SAVR: Medtronic’s Evolut platform linked to cost savings, key benefits for low-risk patients

Two new studies evaluated the long-term impact of choosing TAVR when low-risk patients present with severe aortic stenosis. 

March 12, 2024

Permanent pacemaker implantation after TAVR increases healthcare costs by $24,000 per patient

Researchers say their new analysis, based on five years of U.S. data, highlights just how important it is to keep post-TAVR PPMI rates to a minimum. 

March 5, 2024

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup